Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation

Transplantation

Volumn 92, Issue 6, 2011, Pages 678-685

  Uemura, Tadahiro ^a   Ramprasad, Varun ^a   Matsushima, Kazuhide ^a   Shike, Hiroko ^a   Valania, Tracy ^a   Kwon, Osun ^b   Ghahramani, Nasrollah ^b   Shah, Riaz ^a   Farooq, Umar ^b   Khan, Akhtar ^c   Kadry, Zakiyah ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Alemtuzumab; Graft survival; Pancreas transplant

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY PRODUCTION; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE INFECTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; NEUTROPENIA; PANCREAS TRANSPLANTATION; PLASMAPHERESIS; PNEUMONIA; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; THERAPY RESISTANCE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; CHILD; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 80052657271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822b58be     Document Type: Article

References (39)

1. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19: 705.
2. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118.
3. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
4. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000; 12: 574.
5. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004; 78: 426.
6. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
7. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613.
8. Kato T, Gaynor JJ, Selvaggi G, et al. Intestinal transplantation in children: A summary of clinical outcomes and prognostic factors in 108 patients from a single center. J Gastrointest Surg 2005; 9: 75.
9. Ciancio G, Burke GW III. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15.
10. Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-Long-term results. Am J Transplant 2006; 6: 331.
11. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 1209.
12. Gruessner RW, Kandaswamy R, Humar A, et al. Calcineurin inhibitorand steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005; 79: 1184.
13. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney trans-plantation: Comparison with basiliximab induction-Long-term results. Am J Transplant 2005; 5: 2539.
14. Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88: 810.
15. Matas AJ, Kandaswamy R, Humar A, et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004; 240: 510.
16. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
17. Papadimitriou JC, Drachenberg CB, Wiland A, et al. Histologic grading of acute allograft rejection in pancreas needle biopsy: Correlation to serum enzymes, glycemia, and response to immunosuppressive treatment. Transplantation 1998; 66: 1741.
18. Cashion A, Sabek O, Driscoll C, et al. Correlation of genetic markers of rejection with biopsy findings following human pancreas transplant. Clin Transplant 2006; 20: 106.
19. Troxell ML, Koslin DB, Norman D, et al. Pancreas allograft rejection: Analysis of concurrent renal allograft biopsies and posttherapy follow-up biopsies. Transplantation 2010; 90: 75.
20. Magliocca JF, Odorico JS, Pirsch JD, et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am J Transplant 2008; 8: 1702.
21. Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: Comparison with anti-thymocyte globulin. Transpl Infect Dis 2009; 11: 413.
22. Zanone MM, Favaro E, Quadri R, et al. Association of cytomegalovirus infections with recurrence of humoral and cellular autoimmunity to islet autoantigens and of type 1 diabetes in a pancreas transplanted patient. Transpl Int 2010; 23: 333.
23. Hartmann EL, Gatesman M, Roskopf-Somerville J, et al. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant 2008; 22: 822.
24. Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: A retrospective study. Am J Transplant 2009; 9: 1816.
25. Hurst FP, Belur P, Nee R, et al. Poor outcomes associated with neutropenia after kidney transplantation: Analysis of United States Renal Data System. Transplantation 2010; 92: 36.
26. Peddi VR, Hariharan S, Schroeder TJ, et al. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant 1996; 10(1 Pt 1): 20.
27. Axelrod DA, McCullough KP, Brewer ED, et al. Kidney and pancreas transplantation in the United States, 1999-2008: The changing face of living donation. Am J Transplant 2010; 10 (4 Pt 2): 987.
28. Pascual J, Pirsch JD, Odorico JS, et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreaskidney transplantation. Transplantation 2009; 87: 125.
29. Huang E, Cho YW, Hayashi R, et al. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007; 84: 821.
30. de Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive c4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant 2010; 10: 1660.
31. Fridell JA, Shah A, Milgrom ML, et al. Ipsilateral placement of simultaneous pancreas and kidney allografts. Transplantation 2004; 78: 1074.
32. Muthusamy AS, Vaidya AC, Sinha S, et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant 2008; 8: 2126.
33. Bray RA, Lebeck LK, Gebel HM. The flow cytometric crossmatch. Dual-color analysis of T cell and B cell reactivities. Transplantation 1989; 48: 834.
34. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pancreas allograft rejection: Working proposal by a multidisciplinary international consensus panel. Am J Transplant 2008; 8: 1237.
35. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
36. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
37. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
38. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One-and two-year outcomes. Transplantation 2006; 82: 1621.
39. Clatworthy MR, Sivaprakasam R, Butler AJ, et al. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation 2007; 84: 1563.